FGFR2 and infantile convulsions and choreoathetosis: More recently, selective FGFR inhibitors were introduced for patients with FGFR2 fusion-positive iCCA and resulted in a significant clinical response, prompting phase 2/3 trials and accelerated FDA approvals [18].